PMID- 31138195
OWN - NLM
STAT- MEDLINE
DCOM- 20191230
LR  - 20200309
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 18
IP  - 1
DP  - 2019 May 28
TI  - The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk 
      in patients with type 2 diabetes mellitus.
PG  - 64
LID - 10.1186/s12933-019-0869-2 [doi]
LID - 64
AB  - Canagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor that reduces 
      blood glucose, as well as blood pressure, body weight, and albuminuria in 
      patients with type 2 diabetes mellitus (T2DM). In the CANagliflozin 
      cardioVascular Assessment Study (CANVAS) Program, patients with T2DM and high 
      cardiovascular risk treated with canagliflozin had a significantly lower risk of 
      the composite outcome of cardiovascular death, nonfatal myocardial infarction, or 
      nonfatal stroke; hospitalization for heart failure; and renal outcomes, but also 
      a greater risk of lower-limb amputation. Cardiovascular outcomes trials of some 
      other T2DM agents (i.e., empagliflozin, dapagliflozin, liraglutide, semaglutide, 
      albiglutide) have also shown potential cardiovascular and renal benefits. As a 
      result, diabetes treatment guidelines have begun to incorporate consideration of 
      cardiovascular and renal benefits into their treatment recommendations. 
      Antihyperglycemic agents with proven beneficial cardiovascular effects represent 
      a new opportunity for the diabetologist and cardiologist, in the setting of a 
      multidisciplinary approach, to concomitantly improve glycemic control and reduce 
      the risk of cardiovascular events in patients with T2DM. This review briefly 
      discusses the pharmacology of canagliflozin, including clinical and preclinical 
      data; it also describes the effects of canagliflozin on cardiovascular outcomes 
      and side-effects, and compares these effects with other glucose-lowering agents 
      with proven cardiovascular benefits.
FAU - Carbone, Salvatore
AU  - Carbone S
AD  - Department of Internal Medicine, Pauley Heart Center, Virginia Commonwealth 
      University, West Hospital, Room 529b, 1200 E Broad Street, Richmond, VA, 23298, 
      USA. Salvatore.Carbone@vcuhealth.org.
FAU - Dixon, Dave L
AU  - Dixon DL
AD  - Department of Pharmacotherapy and Outcome Sciences, School of Pharmacy, Virginia 
      Commonwealth University, 410 N. 12th Street, Richmond, VA, 23298, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190528
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0SAC974Z85 (Canagliflozin)
SB  - IM
MH  - Biomarkers/blood
MH  - Blood Glucose/*drug effects/metabolism
MH  - Canagliflozin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/diagnosis/mortality/physiopathology/*prevention & control
MH  - Clinical Trials as Topic
MH  - Diabetes Mellitus, Type 2/blood/diagnosis/*drug therapy/mortality
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Protective Factors
MH  - Risk Assessment
MH  - Risk Factors
MH  - Sodium-Glucose Transporter 2 Inhibitors/adverse effects/*therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC6540565
OTO - NOTNLM
OT  - Canagliflozin
OT  - Diabetes mellitus
OT  - Major adverse cardiovascular event
OT  - Sodium glucose co-transporter 2 inhibitor
COIS- The authors declare that they have no competing interests.
EDAT- 2019/05/30 06:00
MHDA- 2019/12/31 06:00
PMCR- 2019/05/28
CRDT- 2019/05/30 06:00
PHST- 2019/03/22 00:00 [received]
PHST- 2019/05/10 00:00 [accepted]
PHST- 2019/05/30 06:00 [entrez]
PHST- 2019/05/30 06:00 [pubmed]
PHST- 2019/12/31 06:00 [medline]
PHST- 2019/05/28 00:00 [pmc-release]
AID - 10.1186/s12933-019-0869-2 [pii]
AID - 869 [pii]
AID - 10.1186/s12933-019-0869-2 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2019 May 28;18(1):64. doi: 10.1186/s12933-019-0869-2.